[A case of polaprezinc-induced pneumonitis].
A 77-year-old man referred to our hospital three months ago presented with dyspnea on effort and chest radiograph abnormalities. Chest computed tomography showed consolidation and irregular thickening of the peribronchovascular interstitium. Bronchoalveolar lavage fluids showed increases in the percentage of lymphocytes and a decrease of the CD4/8 ratio. Transbronchial lung biopsy specimens showed signs of organizing pneumonia. The patient had been given polaprezinc for the treatment of hypogeusia six months before. A lymphocyte-stimulating test for polaprezinc was positive, and so our diagnosis was polaprezinc-induced pneumonitis.
D000368:Aged; D000370:Ageusia / Q000188:drug therapy; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002336:Carnosine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000473:pathology; D008213:Lymphocyte Activation; D008297:Male; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011014:Pneumonia / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D017967:Zinc Compounds
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D002336:Carnosine